

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

COLO 704

RRID:CVCL_1994

Type: Cell Line

Proper Citation

RRID:CVCL_1994

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1994

Proper Citation: RRID:CVCL_1994

Description: Cell line COLO 704 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:11668190](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22710073](#), [PMID:23839242](#), [PMID:24023729](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Caution: According to DSMZ from a 46 year old female and from ascite fluids while archive documents of Moore G.E. indicate a 50 year old female and from a pleural effusion., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: COLO 704

Synonyms: COLO-704, COLO #704, COLO704, Colorado 704

Cross References: CLO:CLO_0002575, EFO:EFO_0002139, CLDB:cl869, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, BioSample:SAMN03473293, BioSample:SAMN03473372, BioSample:SAMN10988210, cancercellines:CVCL_1994, Cell_Model_Passport:SIDM01719, Cosmic:688095, Cosmic:1707567, DepMap:ACH-001042, DSMZ:ACC-198, DSMZCellDive:ACC-198, EGA:EGAS00001000610, GEO:GSM274700, GEO:GSM659372, GEO:GSM886947, GEO:GSM888015,

GEO:GSM1001490, IGRhCellID:COLO704, LINCS_LDP:LCL-1531,
PharmacDB:COLO704_231_2019, Progenetix:CVCL_1994, Wikidata:Q54814140

ID: CVCL_1994

Record Creation Time: 20220427T215514+0000

Record Last Update: 20260905T174634+0000

Ratings and Alerts

No rating or validation information has been found for COLO 704.

No alerts have been found for COLO 704.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Andr?? P, et al. (2018) Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell, 175(7), 1731.